European Journal of Medical Research - Deutsche AIDS ...
European Journal of Medical Research - Deutsche AIDS ...
European Journal of Medical Research - Deutsche AIDS ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
June 27, 2007 EUROPEAN JOURNAL OF MEDICAL RESEARCH<br />
83<br />
D.11 (Poster)<br />
Virological medical quality management -<br />
7 year follow-up <strong>of</strong> HIV treatment<br />
Knechten H. 1 , Höhn C. 1 , Ehret R. 1 , Wiesmann F. 1 ,<br />
Braun P. 1<br />
1 PZB Aachen, Aachen, Germany<br />
Purpose: The HIV treatment guidelines have been modified recently<br />
and recommend that a viral load 1 diarrhea per day prior to switching vs. 32.8 % <strong>of</strong> pts after<br />
switching. 40.3 % <strong>of</strong> pts used antidiarrheal medication before<br />
switching vs. 30.3 % <strong>of</strong> those afterwards.<br />
Overall Quality <strong>of</strong> Life improved in 27 % and deteriorated<br />
in 10 % <strong>of</strong> pts. 29 % <strong>of</strong> pts experienced fewer loose stools and<br />
11 % reported more. 29 % <strong>of</strong> pts reported less diarrhea and 6<br />
% reported more. In 20 % <strong>of</strong> pts use <strong>of</strong> antidiarrheal medication<br />
was reduced vs. 2 % <strong>of</strong> pts in which the use increased.<br />
75.4 % <strong>of</strong> pts preferred LPV/r TAB therapy, 2.7 % preferred<br />
therapy with LPV/r SGC and 20.3 % judged both therapies<br />
equal (1.5 % n. a.).<br />
Conclusion: In this unselected group <strong>of</strong> patients a trend to<br />
improved Quality <strong>of</strong> Life and reduced GI side effects is observed<br />
after switch from LPV/r SGC to LPV/r TAB.<br />
D.13 (Vortrag)<br />
Long-term efficacy <strong>of</strong> Enfurvitide – final results <strong>of</strong><br />
the RADATA-Fuzeon cohort<br />
H<strong>of</strong>fmann C. 1 , Lorenzen T. 1 , Bogner J.R. 2 , van Lunzen J. 3 ,<br />
Staszewski S. 4 , Arbter P. 5 , Faetkenheuer G. 6 , Gute P. 7 ,<br />
Stoll M. 8 , Hintsche B. 9 , Walther I. 1 , Waesle B. 10 ,<br />
Stoehr A. 1 , Plettenberg A. 1<br />
1 ifi-Institut für interdisziplinäre Medizin, Hamburg, Germany,<br />
2 Medizinische Poliklinik, Klinikum der Universität München<br />
Innenstadt, Infektionsambulanz, München, Germany,<br />
3 Universitätsklinikum Hamburg-Eppendorf,<br />
Ambulanzzentrum Infektiologie, Hamburg, Germany,<br />
4 Universität Frankfurt, HIV-Center, Frankfurt, Germany,<br />
5 Praxis für Allgemeinmedizin, Krefeld, Germany, 6 Klinikum<br />
der Universität zu Köln, Klinik I für Innere Medizin, Köln,<br />
Germany, 7 HIV-Schwerpunktpraxis, Frankfurt, Germany,<br />
8 Medizinische Hochschule Hannover, Abteilung Klinische<br />
Immunologie, Hannover, Germany, 9 Praxis für Innere<br />
Medizin, Berlin, Germany, 10 Roche-Pharma AG, Grenzach-<br />
Wyhlen, Germany<br />
Background: Data on long-term efficacy <strong>of</strong> enfuvirtide outside<br />
clinical trials is limited. In the Radata-Fuzeon cohort,<br />
data <strong>of</strong> HIV-1-infected patients (pts) treated with enfuvirtide<br />
in clinical practice were collected from 32 German centers.<br />
The setting <strong>of</strong>fered planning <strong>of</strong> background therapy according<br />
to resistance analysis, adherence questionnaire, therapeutic<br />
drug monitoring and external expert advice.<br />
Methods: All pts in whom a switch to a new enfuvirtidebased<br />
antiretroviral therapy (ART) was intended were included<br />
in this prospective cohort study. Clinical, immunological<br />
and virological outcomes were measured every three months.<br />
Results: Of 233 pts included, 173 received enfuvirtide and<br />
were eligible for analysis. Pts were heavily pretreated at baseline<br />
(median time on ART: 80 months, number <strong>of</strong> prior regimens:<br />
10), showing a median <strong>of</strong> 7 (range, 1-18) and 2 (range,<br />
1-4) resistance mutations in the reverse transcriptase and in<br />
the protease gene locus, respectively. Pts had a median viral